ReviewBioengineering (Basel, Switzerland)2026
Advances and Prospects in MOF-Based Platforms for Tumor Hyperthermia.
Review in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metal-organic framework (MOF)-based materials have become promising platforms for tumor hyperthermia by integrating energy conversion, tumor microenvironment regulation, and multimodal therapy within programmable porous structures. This review summarizes recent advances in intrinsic MOFs, MOF composites, and MOF-derived materials for photothermal therapy, microwave hyperthermia, and magnetic hyperthermia. The reviewed studies show that high-valence metal MOFs mainly provide stable and modifiable frameworks, whereas transition-metal, magnetic, and multimetallic MOFs contribute to redox regulation, ROS generation, magnetic response, and microwave energy dissipation. Beyond localized heat generation, MOF-based platforms enhance therapeutic efficacy by combining hyperthermia with chemotherapy, chemodynamic therapy, metabolic intervention, immunotherapy, and imaging guidance. These integrated strategies help overcome incomplete ablation, thermotolerance, oxidative stress resistance, and tumor recurrence. However, clinical translation is still limited by insufficient standardization, uncertain degradation behavior, metal-ion safety, and inadequate thermal dose control. Future development should emphasize mechanism-oriented design, controllable composition, long-term biosafety, and image-guided thermal regulation to advance MOF-based hyperthermia toward precise and clinically relevant cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.